文献速递临床试验与 GCP

重症患者经肠内营养以阶梯式方法补充蛋白质:REPLENISH随机临床试验方案

Replacing protein via enteral nutrition in a stepwise approach in critically ill patients: the REPLENISH randomized clinical trial protocol.
PubMed 文献 · Trials · 2023-07-30

REPLENISH是一项开放标签、多中心随机临床试验,计划纳入2502例成人机械通气重症患者,比较在标准肠内营养配方基础上从ICU第5天起补充肠内蛋白质1.2 g/kg/天使总量达2–2.4 g/kg/天,与不补充使总量达0.8–1.2 g/kg/天,对90天全因死亡率的影响。

要点

  • 补充蛋白组从ICU第5天起额外补充肠内蛋白质1.2 g/kg/天,使肠内蛋白总量达2–2.4 g/kg/天。
  • 对照组仅接受主治团队按常规给予的肠内配方,肠内蛋白总量达0.8–1.2 g/kg/天。
  • 主要结局为90天全因死亡率,其他结局包括90天功能与生活质量评估。

核心结论

  • 研究假设:在标准肠内营养配方基础上补充肠内蛋白质使总量达2–2.4 g/kg/天,相比不补充使总量达0.8–1.2 g/kg/天,可降低成人机械通气重症患者的90天全因死亡率。
  • 研究已于2021年9月启动,计划在目标样本量的三分之一和三分之二时进行中期分析,预计2025年底完成。

研究设计与样本

  • REPLENISH为开放标签、多中心随机临床试验,计划纳入2502例患者。
  • 患者随机分为补充蛋白组或对照组,两组均按主治团队给予基础肠内配方,该配方含蛋白质最高1.2 g/kg/天。
  • 补充蛋白组从ICU第5天起额外补充肠内蛋白质1.2 g/kg/天,对照组接受基础配方而不补充蛋白质。
  • 主要结局为90天全因死亡率,其他结局包括90天功能与生活质量评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protein intake is recommended in critically ill patients to mitigate the negative effects of critical illness-induced catabolism and muscle wasting. However, the optimal dose of enteral protein remains unknown. We hypothesize that supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition formula to achieve high amount of enteral protein (range 2-2.4 g/kg/day) given from ICU day 5 until ICU discharge or ICU day 90 as compared to no supplemental enteral protein to achieve moderate amount enteral protein (0.8-1.2 g/kg/day) would reduce all-cause 90-day mortality in adult critically ill mechanically ventilated patients. METHODS: The REPLENISH (Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients) trial is an open-label, multicenter randomized clinical trial. Patients will be randomized to the supplemental protein group or the control group. Patients in both groups will receive the primary enteral formula as per the treating team, which includes a maximum protein 1.2 g/kg/day. The supplemental protein group will receive, in addition, supplemental protein at 1.2 g/kg/day starting the fifth ICU day. The control group will receive the primary formula without supplemental protein. The primary outcome is 90-day all-cause mortality. Other outcomes include functional and quality of life assessments at 90 days. The trial will enroll 2502 patients. DISCUSSION: The study has been initiated in September 2021. Interim analysis is planned at one third and two thirds of the target sample size. The study is expected to be completed by the end of 2025. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04475666 . Registered on July 17, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Arabi YM, Al-Dorzi HM, Sadat M, et al. Replacing protein via enteral nutrition in a stepwise approach in critically ill patients: the REPLENISH randomized clinical trial protocol. Trials. 2023. PMID: 37518058. doi:10.1186/s13063-023-07507-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。